SCHWARZ PHARMA announces agreement with OTSUKA for jointly marketing Pletal® in Germany
December 11, 2006 - SCHWARZ PHARMA today announced that SCHWARZ
PHARMA Deutschland GmbH has signed an agreement with Otsuka Pharma-
ceutical Europe Ltd., UK on the joint marketing of Pletal® in Germany.
Pletal® (cilostazol, developed by Otsuka) is an oral treatment drug for stage II
peripheral arterial occlusive disease (intermittent claudication) that has already
been proved to be of benefit in the USA, Japan and the UK. This drug is now
“We are happy to have the opportunity to market Pletal® in cooperation with
says Konstantin von Alvensleben, General Man-
ager of SCHWARZ PHARMA Deutschland GmbH. “For the drug complements
our in the field of vascular medicine established product Prostavasin® and
hence offers patients and doctors an expanded range of options for treating this
Intermittent claudication, stage II peripheral arterial occlusive disease, is char-
acterized by cramp-like pains in the legs which occur due to circulatory prob-
lems after walking a certain distance and disappear again after a period of rest.
If the disease is not treated, there is a risk the symptoms will get worse, with
the possibility that the distance walked without pain may be shortened further,
pain may also occur when at rest, leading all the way to the risk of amputation.
Several hundred thousand patients (in Germany almost 20% of those over 65
years of age are affected) could benefit from this drug, where the correspond-
ing development program showed a clinically relevant and statistically signifi-
cant improvement of symptoms. In addition, the use of Pletal® in treating these
patients is also supported by international guidelines.
With both drugs, Pletal® and Prostavasin®, SCHWARZ PHARMA offers options
for the treatment for all phases of peripheral arterial occlusive disease (PAOD).
SCHWARZ PHARMA (headquartered in Monheim, Germany) is a stock listed company with approximately 4,400 employees worldwide. The company develops novel medicines in the therapeutic areas of the central nervous system. Furthermore it markets innovative drugs focused to treat cardiovascular and gastro-intestinal diseases. In 2005 the SCHWARZ PHARMA group achieved global sales of nearly € 1 billion. The company has a strong international presence with subsidiaries in Europe, USA and Asia. Contact: Antje Witte, Tel: +49 2173 48 1866; Bettina Ellinghorst, Tel.: +49-2173 48 2329 SCHWARZ PHARMA Deutschland GmbH, Karl-Heinz Lüninghöner, Tel.: +49 2173 48 3107
Founded in 1964, OTSUKA PHARMACEUTICAL Co., Ltd. is a global healthcare company with the mission statement: “Otsuka — people creating new products for better health worldwide.”
ops, manufactures and markets innovative, original products, focusing its core businesses on pharmaceutical products for the treatment of disease and consumer products for the maintenance of everyday health. Otsuka is committed to being a corporation that creates global value, adhering to the high ethical standards required of a company involved in health and life, maintaining a dynamic corporate culture, and working in harmony with local communities and the environment. The Otsuka Pharmaceutical Group comprises 87 companies and employs approximately 27,000 people in 17 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned € 5.3 billion in annual reve- nues in fiscal 2005. Contact: Rina Sanchome, Tel: +49 69 170086-18; Alison Ross, Tel: +44 1895 207 100 This press release contains forward-looking statements based on current plans, estimates and beliefs of the management of SCHWARZ PHARMA AG. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking state- ments contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation affecting SCHWARZ PHARMA AG, exchange rate fluctuations and hiring and retention of its em- ployees. All SCHWARZ PHARMA press releases are distributed by e-mail at the same time they become available on the website. Please go to www.schwarzpharma.com, press room, news subscription to register online, change your selection or discontinue this service.
Northlake Hospital Inpatient Rounding List (Note: Real data imported from Meditech, but names and MRNs have been modified) Demographics Diagnosis XXXX, XXXXXX meds: clonidine hcl 0.1 mg po tidp/prn, estrogens,conjugated 0.625 mg po qd, lisinopril 20 mg po qd, methimazole 10 mg po qd, normal Acct: 92833182 saline 10 ml iv qshift, normal saline 10 ml iv prn/